Toxicity

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

Retrieved on: 
Tuesday, April 2, 2024
TUSC2, Toxicity, LLC2, Gene, Growth, NSCLC, Diabetes, Risk, Patient, Lung, Neoplasm, Glioma, Mouse, Manuscript, Cancer, Pembrolizumab, NPRL2, Lung cancer, Stomach, BioRxiv, Hepatocellular carcinoma, NK, Natural killer T cell

AUSTIN, Texas, April 2, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing the Company's non-viral Oncoprex® Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer (NSCLC) in a humanized mouse model.

Key Points: 
  • Genprex's Oncoprex® Delivery System is a novel non-viral approach that utilizes lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor genes deleted during the course of cancer development.
  • Genprex believes this system allows for delivery of a number of cancer-fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer.
  • "These positive preclinical data are very encouraging and support NPRL2 gene therapy as a potential treatment for a sub-group of NSCLC in which patients traditionally are resistant to existing therapies," said Rodney Varner, President, Chairman and Chief Executive Officer at Genprex.
  • In conclusion, researchers reported that NPRL2 gene therapy induces anti-tumor activity through dendritic cell-mediated antigen presentation and cytotoxic immune cell activation.

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Retrieved on: 
Tuesday, April 2, 2024
Toxicity, Radiation, Sintilimab, NMPA, Endometrial cancer, Disease, DCR, New Drug Application, Patient, Neoplasm, NDA, Cancer, Breakthrough therapy, Senior, HCM, HKEX, Dor, IRC, Prognosis, PFS, Ophthalmology, Pharmaceutical industry

The NDA is supported by data from FRUSICA-1, the endometrial cancer registration cohort of a multi-center, open-label Phase 2 study investigating sintilimab in combination with fruquintinib in endometrial cancer patients who experienced disease recurrence, disease progression or intolerable toxicity  with treatment on platinum-based doublet chemotherapy.

Key Points: 
  • The NDA is supported by data from FRUSICA-1, the endometrial cancer registration cohort of a multi-center, open-label Phase 2 study investigating sintilimab in combination with fruquintinib in endometrial cancer patients who experienced disease recurrence, disease progression or intolerable toxicity  with treatment on platinum-based doublet chemotherapy.
  • We are excited about the NDA acceptance and priority review designation, which increases our potential to bring a new treatment option to endometrial cancer patients, and concurrently strengthens the leadership position of TYVYT® in China."
  • We look forward to bringing this much-awaited treatment advancement to endometrial cancer patients to improve their treatment outcome."
  • The NMPA granted Breakthrough Therapy designation to the combination of sintilimab and fruquintinib for this potential indication in July 2023.

$50 billion opportunity emerges for insurers worldwide from generative AI's potential to boost revenues and take out costs

Retrieved on: 
Monday, April 1, 2024
Insurance, Toxicity, Lifting, Financial services, Research, Hallucination, Interview, AI

BOSTON, April 1, 2024 /PRNewswire/ -- Insurance businesses worldwide have a $50 billion dollar financial opportunity from generative AI to harness the technology in ways that could boost their revenues by as much as 20% and cut their costs by up to 15%, research from Bain & Company released today finds.

Key Points: 
  • "For insurers, benefits due to generative AI will come through three routes," said Bhavi Mehta , global lead of AI in Financial Services at Bain.
  • At Bain, we remain committed to helping our clients not only within insurance ‒ but across industries ‒ identify and realize AI's full business potential."
  • Bain's analysis also pinpoints key risk areas emerging from insurers' developing use of generative AI including hallucination, data provenance, misinformation, toxicity, and intellectual property ownership.
  • As generative AI continues to evolve, Bain urges insurance companies to take several critical steps to adapt to the fast-developing technology.

MARITIME INDUSTRY LEADERS TO EXPLORE AMMONIA AS MARINE FUEL IN THE US WEST COAST

Retrieved on: 
Friday, March 29, 2024
Toxicity, MOU, Government, Sumitomo Group, Safety, Business, GHG, Port of Oakland, Terminal, Lead, Transport, International Maritime Organization, Fleet Management Limited, Sumitomo Corporation, ABS, American Bureau of Shipping, Multimedia, LNG, Study, AFV, Warehouse

This Study will be conducted at the Port of Oakland, Benicia and nearby major ports in U.S. West Coast.

Key Points: 
  • This Study will be conducted at the Port of Oakland, Benicia and nearby major ports in U.S. West Coast.
  • CALAMCO is a California based cooperative composed of grower members, as well as the largest ammonia distributer in California.
  • Safety assessments are critical to formulate standards for use of ammonia as a marine fuel due to the toxicity of the substance.
  • Dan Stone, President at CALAMCO, said, "We are excited to support the exploration of ammonia bunkering in the US West Coast.

Promising New Data Published on Potential Therapy to Boost Effectiveness of Pancreatic Cancer Treatments

Retrieved on: 
Tuesday, March 26, 2024
Toxicity, Cell, Development, Survival, BLR, Disease, American Cancer Society, PNAC, Research, University, Quality of life, Cancer, IND, Pharmacology, Pancreatic cancer, Mario, Potential, RFU, Therapy, Helix, Person, Pharmaceutical industry

The data points to a promising strategy to boost the effectiveness of existing drugs in pancreatic cancer and other solid-tumor cancers.

Key Points: 
  • The data points to a promising strategy to boost the effectiveness of existing drugs in pancreatic cancer and other solid-tumor cancers.
  • According to the American Cancer Society , some 66,000 persons in the U.S. are diagnosed annually with pancreatic cancer, a disease with a very low survival rate that is projected to take 51,000 lives in 2024.
  • "Finding an approach to use lower doses while maintaining efficacy has been a constant search for cancer treatments."
  • "BLR-100 targets the formation of the protective tumor stroma, a fibrotic-like element that is thought to retard the entry of chemo-therapeutic agents."

Melanin Gamers and The Watch Launch the First Rating System Identifying Online Gaming Toxicity

Retrieved on: 
Tuesday, March 26, 2024
Racism, Toxicity, Culture, Organization, ESRB, Pressure, Environment, Hope, Ipsos-Reid, CCO, Pejorative, Verbal abuse, The Watch, Video, Parent, Movement, Video game

TORONTO, March 26, 2024 /PRNewswire/ - Melanin Gamers , a digital community protecting and promoting diversity and inclusion in the video game industry announced today a toxicity rating system with a singular goal – to eliminate harmful and verbal abuse within gaming culture.

Key Points: 
  • TORONTO, March 26, 2024 /PRNewswire/ - Melanin Gamers , a digital community protecting and promoting diversity and inclusion in the video game industry announced today a toxicity rating system with a singular goal – to eliminate harmful and verbal abuse within gaming culture.
  • Ideally The Watch rating would be paired with existing accepted ratings, to offer parents and players alike more information about what to expect beyond the storylines of the games.
  • To forge and inform The Watch, Melanin Gamers, Leo Burnett, and The Angus Reid Group, surveyed hundreds of gamers across some of the biggest gaming communities.
  • This toxicity rating is hopefully another step forward as we look to transform the gaming culture and promote an environment built on the tenets of inclusivity, kindness, and respect," said Annabel Ashalley-Anthony, founder of Melanin Gamers.

Melanin Gamers and The Watch Launch the First Rating System Identifying Online Gaming Toxicity

Retrieved on: 
Tuesday, March 26, 2024
Racism, Toxicity, Culture, Organization, ESRB, Pressure, Environment, Hope, Ipsos-Reid, CCO, Pejorative, Verbal abuse, The Watch, Video, Parent, Movement, Video game

TORONTO, March 26, 2024 /PRNewswire/ -- Melanin Gamers, a digital community protecting and promoting diversity and inclusion in the video game industry announced today a toxicity rating system with a singular goal – to eliminate harmful and verbal abuse within gaming culture. Ideally The Watch rating would be paired with existing accepted ratings, to offer parents and players alike more information about what to expect beyond the storylines of the games.

Key Points: 
  • TORONTO, March 26, 2024 /PRNewswire/ -- Melanin Gamers , a digital community protecting and promoting diversity and inclusion in the video game industry announced today a toxicity rating system with a singular goal – to eliminate harmful and verbal abuse within gaming culture.
  • Ideally The Watch rating would be paired with existing accepted ratings, to offer parents and players alike more information about what to expect beyond the storylines of the games.
  • To forge and inform The Watch, Melanin Gamers, Leo Burnett, and The Angus Reid Group, surveyed hundreds of gamers across some of the biggest gaming communities.
  • This toxicity rating is hopefully another step forward as we look to transform the gaming culture and promote an environment built on the tenets of inclusivity, kindness, and respect," said Annabel Ashalley-Anthony, founder of Melanin Gamers.

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

Retrieved on: 
Friday, March 22, 2024
Diagnosis, ESC, Toxicity, ERA, Tadalafil, Internal medicine, European Respiratory Society, Disease, Risk, Pulmonary hypertension, Patient, PVR, Mitigation, Female, Nitric oxide, Connective tissue disease, Orthostatic hypertension, World Health Organization, PDE5, Johnson & Johnson, REMS, WHO, Pulmonary circulation, PAH, FDA, Constriction, ERS, Food, Pharmaceutical industry

RARITAN, N.J., March 22, 2024  /PRNewswire/ -- Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI® – a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor – for the chronic treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group I) and WHO functional class (FC) II-III.1 OPSYNVI® may be used in patients with PAH who are treatment-naïve or who are already on an ERA, PDE5 inhibitor or both. OPSYNVI® may be used in patients who are currently treated concomitantly with stable doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets.1

Key Points: 
  • Historically, this required patients to take multiple pills because no single-tablet combination therapy targeting two or more pathways was available," said Kelly Chin, M.D., Professor of Internal Medicine and Director of the Pulmonary Hypertension Program at UT Southwestern Medical Center, and an investigator in the A DUE study.
  • The FDA's approval of OPSYNVI® is based on the results from the pivotal Phase 3 A DUE study , in which OPSYNVI® demonstrated greater reduction in Pulmonary Vascular Resistance (PVR) after 16 weeks versus tadalafil or macitentan monotherapy.
  • "People with PAH often live with the burden of taking many pills each day, which can pose challenges," said James F. List, M.D., Ph.D., Global Therapeutic Area Head, whose team oversees a portfolio of programs including Pulmonary Hypertension at Johnson & Johnson.
  • "We're thrilled to bring this single-tablet combination therapy to patients, as it has the potential to optimize disease management and fulfill a significant unmet need in supporting recently updated treatment guidelines that call for initial or early combination treatment."

Spectrum Dynamics is proud to announce the Installation of the VERITON-CT SPECT/CT imaging system at European Leading Cancer Center, Gustave Roussy

Retrieved on: 
Thursday, March 21, 2024
Toxicity, CZT, Algorithm, Patient, Neoplasm, Hospital, 3D, Cancer, Gustave Roussy, Google Images, The, SPECT, SPECT/CT, Newsweek, Nuclear medicine, Health, Medical imaging

Gustave Roussy is considered as a leading cancer centre in Europe.

Key Points: 
  • Gustave Roussy is considered as a leading cancer centre in Europe.
  • The institute treats patients with all types of cancer at any age and is a leading institution in the treatment of rare and complex tumors.
  • It is unlike any other ring-shaped gantry, with a 360o CZT 12-detector design that automatically moves close to the patient's body.
  • "We are delighted to collaborate with Gustav Roussy with the install of the VERITON-CT 400 SPECT/CT scanner," says Johann Fernando, Executive Vice President, Spectrum Dynamics.

CPSC Warns that Narcotics and Water Beads Are Growing Risks Facing Young Children

Retrieved on: 
Tuesday, March 19, 2024
Narcotic, Toxicity, National Poison Prevention Week, Poisoning, Environment, CPSC, Caregiver, Risk, Child, Acrylamide, Paracetamol, Death, Heart, Water, Safety, Injury, Ibuprofen

WASHINGTON, March 19, 2024 /PRNewswire/ -- During National Poison Prevention Week, the U.S. Consumer Product Safety Commission (CPSC) is highlighting serious, growing hazards facing young children, including a surge in unintentional poisoning from narcotics, and additional hazards identified with water bead products. 

Key Points: 
  • WASHINGTON, March 19, 2024 /PRNewswire/ -- During National Poison Prevention Week, the U.S. Consumer Product Safety Commission (CPSC) is highlighting serious, growing hazards facing young children, including a surge in unintentional poisoning from narcotics, and additional hazards identified with water bead products.
  • The large water beads in CPSC's warnings contain levels of acrylamide in violation of the Federal Hazardous Substances Act.
  • CPSC Recommendation: Remove water beads from any environment where young children may be present.
  • Store water beads in a secure container and location where young children cannot easily access them.